Kalaris Reports Full Year 2025 Financial Results and Provides Business Updates Positive initial data reported from Phase 1a Single Ascending Dose study in nAMD in December 2025; preliminary data from ongoing Phase 1b/2 study expected in 1H 2027 Intend to initiate Phase 3 clinical trials by year-end 2027 Completed oversubscribed $50.0 million private placement in December 2025

#KLRS Kalaris Reports Full Year 2025 Financial Results and Provides Business Updates

www.stocktitan.net/news/KLRS/kalaris-report...

Kalaris Therapeutics Announces Oversubscribed $50.0 Million Private Placement Kalaris Therapeutics, Inc. (NASDAQ: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced that it has entered into a

#KLRS Kalaris Therapeutics Announces Oversubscribed $50.0 Million Private Placement

www.stocktitan.net/news/KLRS/kalaris-therap...

Kalaris Therapeutics Reports Positive Initial Phase 1a Data for TH103 in Treatment-Naïve Neovascular AMD Kalaris Therapeutics (NASDAQ: KLRS) reported positive initial Phase 1a single ascending dose data for TH103 in treatment‑naïve neovascular AMD (N=13) with three dose levels (0.5 mg, 1.5 mg, 2.5 mg) and 6 months follow‑up. Key outcomes at Month 1 included a mean +10‑letter BCVA, −129 μm central subfield thickness (CST), and ~95% reduction in central intraretinal fluid. Pharmacokinetics showed dose‑adjusted plasma Cmax 27–51‑fold lower versus current leading agents. After one injection, 31% of patients required no additional anti‑VEGF treatment through 6 months. Two transient cases of intraocular inflammation at 2.5 mg were attributed to host cell protein; manufacturing was updated and no new IOI cases were seen with purified material. Kalaris is accelerating its Phase 1b/2 multi‑ascending dose study and expects preliminary data in 2H 2026. Conference call/webcast held today at 4:30 PM ET.

#KLRS Kalaris Therapeutics Reports Positive Initial Phase 1a Data for TH103 in Treatment-Naïve Neovascular AMD

www.stocktitan.net/news/KLRS/kalaris-therap...

#KLRS Kalaris Reports Third Quarter 2025 Financial Results and Provides Business Updates

www.stocktitan.net/news/KLRS/kalaris-report...

80-Patient Phase 1b/2 Trial: Kalaris Tests Revolutionary AMD Drug from Lasker Award Winner Kalaris advances TH103 in 80-patient macular degeneration study with 4 monthly doses. Phase 1a data expected Q4 2025, Phase 1b/2 results in 2H 2026. Led by VEGF pioneer Dr. Ferrara.

#KLRS UPDATE – Kalaris Therapeutics Now Enrolling Phase 1b/2 Multiple Ascending Dose Study of TH103 in Neovascular Age-Related Macular Degeneration

www.stocktitan.net/news/KLRS/update-kalaris...

Novel Anti-VEGF Drug TH103 Enters Key Phase 1b/2 Trial: Kalaris Tests Breakthrough AMD Treatment Kalaris initiates 80-patient Phase 1b/2 multiple ascending dose study of TH103 for neovascular AMD. Trial includes 4 monthly doses, with initial data expected 2H 2026. Phase 1a results due Q4 2025.

#KLRS Kalaris Therapeutics Now Enrolling Phase 1b/2 Multiple Ascending Dose Study of TH103 in Neovascular Age-Related Macular Degeneration

www.stocktitan.net/news/KLRS/kalaris-therap...

Kalaris Eyes Q4 Data Readout for Novel Macular Degeneration Drug as Cash Position Hits $88M Clinical-stage biotech advances Phase 1 trial of TH103 for macular degeneration, strengthens leadership team, and maintains $88.4M cash runway through Q4 2026. See pipeline details.

#KLRS Kalaris Reports Second Quarter 2025 Financial Results and Provides Business Updates

www.stocktitan.net/news/KLRS/kalaris-report...

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks with strong volume declines, Thu Jul 17th - #NEXM #CEPO #PDSB #NB #KLRS #GAME #CDNA #BCLI #OPAD #EB - More: crystalequityresearch.com/SmCpStr/ - #smallcap

Kalaris Reports First Quarter 2025 Financial Results and Provides Business Highlights Kalaris Therapeutics (NASDAQ: KLRS) reported its Q1 2025 financial results and provided business updates. The company is advancing its Phase 1 trial of TH103, a novel anti-VEGF treatment for neovascular age-related macular degeneration (nAMD). Initial clinical data is expected in Q4 2025.Financial highlights include cash and cash equivalents of $101.0 million as of March 31, 2025, up from $1.6 million in December 2024, primarily due to the AlloVir merger. The company reported a net loss of $10.2 million ($2.52 per share) compared to $3.4 million ($2.60 per share) in Q1 2024. R&D expenses increased to $6.0 million from $2.0 million, while G&A expenses rose to $4.3 million from $0.6 million year-over-year.

#KLRS Kalaris Reports First Quarter 2025 Financial Results and Provides Business Highlights

www.stocktitan.net/news/KLRS/kalaris-report...